Market Overview

Otsuka Pharmaceutical Completes Acquisition of Visterra

Share:

Visterra, Inc. (Visterra) announces that Otsuka Pharmaceutical Co., Ltd.
of Japan has completed the acquisition of Visterra for approximately USD
430 million in an all-cash transaction. The acquisition was completed on
August 31, 2018. Visterra will operate as a wholly owned subsidiary of
Otsuka America, Inc., which is a U.S. holding company and a wholly owned
subsidiary of Otsuka Pharmaceutical Co., Ltd. of Japan.

Otsuka Pharmaceutical Co., Ltd. has issued this announcement in Japan.

About Visterra, Inc.
Visterra is a clinical stage
biotechnology company committed to developing innovative antibody-based
therapies for the treatment of patients with kidney diseases and other
hard-to-treat diseases. Its proprietary Hierotope® platform enables the
design and engineering of precision antibody-based product candidates
that specifically bind to, and modulate, key disease targets that are
not adequately addressed by traditional therapeutic approaches. The
platform also includes Fc engineering capabilities for half-life
extension, bispecific antibodies and antibody-drug conjugates (ADCs).
Visterra's pipeline includes programs targeting IgA nephropathy and
other kidney diseases, cancer, chronic pain and infectious diseases.
Visterra is funded by investments by Polaris Partners, Flagship
Pioneering, the Bill and Melinda Gates Foundation, MRL Ventures Fund,
Vertex Global Healthcare Fund, Serum Institute of India Private Ltd.,
Temasek Holdings, Omega Funds, Cycad Group, Lux Capital, Alleghany
Financial Group Ventures, CTI Life Sciences Fund and Alexandria
Equities. For more information, visit www.visterrainc.com.

About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical
is a global healthcare company with the corporate philosophy:
"Otsuka-people creating new products for better health worldwide."
Otsuka researches, develops, manufactures and markets innovative
products, with a focus on pharmaceutical products for the treatment of
diseases and nutraceutical products for the maintenance of everyday
health.

In pharmaceuticals, Otsuka is a leader in the challenging area of mental
health and also has research programs in several under-addressed
diseases including tuberculosis, a significant global public health
issue. These commitments illustrate how Otsuka is a "big venture"
company at heart, applying a youthful spirit of creativity in everything
it does.

Otsuka Pharmaceutical is a subsidiary of Otsuka Holdings Co., Ltd.
headquartered in Tokyo, Japan. The Otsuka group of companies employed
46,000 people worldwide and had consolidated sales of approximately USD
11.1 billion in 2017.

All Otsuka stories start by taking the road less travelled. Learn more
about Otsuka Pharmaceutical Company on its global website at https://www.otsuka.co.jp/en.
Learn more about Otsuka in the U.S. at www.otsuka-us.com
and connect with us on Twitter at @OtsukaUS.

View Comments and Join the Discussion!